MA18.03 Preliminary Safety and Treatment Data of A Phase 3 Trial: Hypofractionated vs Conventional Fractionated Concurrent Chemoradiation for LS-SCLC

Concurrent chemoradiotherapy is the standard of care in limited-stage small-cell lung cancer (LS-SCLC), but the optimal radiotherapy schedule and dose remains controversial. Recently, characterized by the improved dose conformality to tumor target and reduced normal tissue exposure, intensity-modulated radiation therapy (IMRT) has been used widely, making hypo-fractionated radiotherapy (HypoRT) for LS-SCLC feasible. The aim of this study was to determine whether a 3-week schedule of HypoRT is as efficacious and safe as a 6-week schedule of conventional fractionated radiotherapy (ConvRT) with concurrent chemotherapy in LS-SCLC.